Competitive generic therapy, the FDA program for drugs with one maker

On Aug. 8, 2018, FDA approved a generic potassium chloride oral solution in two strengths. It was the first entry on what has become a list of 531 approvals, all for drugs that had at most one generic competitor when the applicant asked for help. FDA's Competitive Generic Therapy Approvals list¹, current as of Oct. 22, 2026, records every one of them, and marks which earned a reward for getting there first.

A gap in the older generic incentives explains why the program exists. Many old, off-patent drugs are made by one company, or by a brand and a single generic. With no patent left to challenge, the 180-day exclusivity that goes to a first Paragraph IV filer does not apply, and a small market can make the product unattractive to copy even though nothing legally blocks it. Thin markets like these were where many of the generic price spikes of 2013 to 2015 happened.

Congress answered in the FDA Reauthorization Act of 2017⁴, signed on Aug. 18, 2017. Section 803 added section 506H to the Federal Food, Drug, and Cosmetic Act, letting FDA designate a drug as a competitive generic therapy (CGT) and speed its development and review. Section 808 created a separate 180-day exclusivity for the first approved CGT applicant. Eight years of approvals now show how much the program has grown, and how often designated products end up without that exclusivity.

The one-competitor test

Designation turns on "inadequate generic competition." Under 21 U.S.C. 356h³, that exists when there is not more than one approved drug in the active section of the Orange Book⁷ that is either the reference listed drug or a generic referencing it. Discontinued products do not count. GxRadar's explainer on the Orange Book covers how products move between the active and discontinued sections.

FDA's guidance, revised in October 2022², adds working rules. Designation is specific to each strength. The request must come before or with the original ANDA, and requests filed later are generally untimely. Each application needs its own request, and FDA aims to respond within 60 days based on what the Orange Book shows at that time.

What a designation buys during development

On request, FDA can hold product development and pre-submission meetings, give timely advice, put senior reviewers on the file and assign a cross-disciplinary project lead, according to the guidance. During review it can use mid-cycle meetings and coordinated assessment across disciplines.

A designation does not by itself shorten the review clock set under the generic drug user fee program (see how GDUFA works). A designated ANDA may still qualify for priority review under FDA's separate prioritization policy, MAPP 5240.3⁸, which can shorten it. Within one year after approval, the applicant must report to FDA whether the drug has been marketed.

Two kinds of 180-day exclusivity

Exclusivity is the stronger incentive, and its rules differ from the older one in ways that matter. The patent-challenge version dates to the Hatch-Waxman Act of 1984 and was rewritten by the Medicare Modernization Act of 2003⁶, which added the forfeiture provisions; FDA's patents and exclusivity FAQ⁵ summarizes how it works.

That 75-day rule is the design choice that sets CGT apart. Under the patent-challenge version, covered in GxRadar's piece on 180-day exclusivity, a first filer can sometimes hold the period for a long time without launching. A CGT first approved applicant that has not started marketing within 75 days forfeits its eligibility. FDA counts the days from the calendar day after approval takes effect. Applicants may also give up the exclusivity, and the guidance recommends they tell FDA when marketing begins, since the agency generally learns of a launch only that way.

What 531 approvals show

FDA updates the list on a bi-weekly basis¹. Counting it by approval year, and setting each year against the total of original ANDA approvals in openFDA's Drugs@FDA data⁹ (the same series behind GxRadar's approvals tracker), gives a rough sense of the program's weight.

These two series come from different FDA datasets and are counted by calendar year, so the share is an approximation. Even so, CGT approvals went from fewer than 1 percent of original generic approvals in 2018 to roughly one in seven in 2025.

Of the 531, FDA marks 221 as eligible for CGT exclusivity for at least one strength and 310 as not eligible. Among the eligible products, the forfeiture column shows a forfeiture for 43, at least for some strengths, and one entry is marked as relinquished. Because designation and exclusivity are both strength-specific, several entries show a split, with one strength eligible and others not. The list counts approvals only; a designated ANDA appears once approved, and FDA does not publish a running count of designations granted.

Why most designated products get no exclusivity

FDA says so directly on the list page: "receiving a CGT designation does not ensure that a drug product will be eligible for CGT exclusivity." The example it gives¹ is the patent condition. If any unexpired patent or exclusivity was listed in the Orange Book when the original ANDA was submitted, the product cannot earn CGT exclusivity, though it keeps the review support. A product also misses out if another applicant reaches approval first, since there is only one exclusivity period for each CGT.

Each approval adds at least one more approved source for a drug where one maker, or a brand and one generic, supplied the US market. Whether that turns into steady supply and lower prices depends on the new maker launching and staying, which is what the 75-day rule and the one-year marketing report push toward. GxRadar's analysis of how prices fall as competitors enter shows why the second and third makers count for so much. Whether a newly approved generic is stocked locally, and whether it carries an AB rating for substitution (see therapeutic equivalence codes), is a question a pharmacist can answer.